Abstract Library

#2773 Impact on Outcome in Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) Included in Prospective Clinical Trials (CT)

Introduction: Access to CT offers cancer pts the opportunity to receive new treatments and better monitoring of efficacy and toxicity. The increase of systemic therapy options in advanced NENs has relegated the inclusion of pts in CT to later lines of treatment as suggested in most guidelines.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Vukovic P, Garcia-Alvarez A, Díaz N, Cameselle-Garcia S,

Keywords: Clinical Trial, Neuroendocrine Neoplasms, Overall Survival,

#2251 Neuroendocrine Testicular Tumour. An Unusual Issue.

Introduction: Neuroendocrine tumours can arise from neuroendocrine cells throughout the body. Location on testis is rare, accounting less than 1% of all testicular malignancies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Landa A, Otaño M, Diaz M, Sánchez B, Sagastibeltza N,

Keywords: neuroendocrine, testicular cancer,

#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma

Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davi' M

Authors: Zambon G, Cosaro E, Cingarlini S, Trombetta M, Landoni L,

Keywords: pasireotide, malignant insulinoma, hypoglycemia,

#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mansfield A

Authors: Mansfield A, Aggarwal R, Beltran H, Farago A, Hann C,

Keywords: Rovalpituzumab tesirine, DLL3, neuroendocrine tumors, antibody-drug conjugate,

#2124 A Case Report of a Malignant Insulinoma

Introduction: Despite rare (1-2% of pancreatic tumors/PT), insulinomas are the most common functional pNET. The diagnosis is established by demonstrating inappropriately high serum insulin levels during a spontaneous or induced episode of hypoglycemia.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Zoumblios C, Tegos T, Kyriakopoulos G, Argyrakos T, Alevizopoulos N,

Keywords: malignant, insulinoma,